| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
 COVID-19 portal |
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.[1][2][3][4]
On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.[5]
References
- ^ "Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial". Bavarian Nordic. 8 March 2021. Retrieved 13 April 2021.
- ^ Clinical trial number NCT04839146 for "Safety and Tolerability of ABNCoV2 (COUGH-1)" at ClinicalTrials.gov
- ^ "Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine". Bavarian Nordic. 23 August 2021. Retrieved 24 August 2021.
- ^ Clinical trial number NCT05077267 for "ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects" at ClinicalTrials.gov
- ^ Svansø VL (9 August 2021). "Foreløbige resultater: Dansk vaccine virker i første forsøg med mennesker – og den virker godt". Berlingske.dk (in Danish). Retrieved 25 January 2023.
Scholia has a profile for ABNCoV2 (Q108471697).
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 24 August 2023, at 14:16